Simvastatin reduces venous stenosis formation in a murine hemodialysis vascular access model

Kidney International

Volumn 84, Issue 2, 2013, Pages 338-352

  Janardhanan, Rajiv ^a   Yang, Binxia ^a   Vohra, Pawan ^a   Roy, Bhaskar ^a   Withers, Sarah ^a   Bhattacharya, Santanu ^b   Mandrekar, Jaywant ^a   Kong, Hyunjoon ^c   Leof, Edward B ^b   Mukhopadhyay, Debabrata ^b   Misra, Sanjay ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Arteriovenous fistula; Chronic kidney disease; Murine model; Restenosis; Veins

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CASPASE 3; GELATINASE A; GELATINASE B; PHOSPHATE BUFFERED SALINE; PLACEBO; SIMVASTATIN; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOVENOUS FISTULA; ARTICLE; CAROTID ARTERY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG PROTEIN BINDING; DRUG TARGETING; FIBROBLAST; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; HEMODIALYSIS; IN VITRO STUDY; IN VIVO STUDY; JUGULAR VEIN; MALE; MMP 9 GENE; MOUSE; MYOFIBROBLAST; NEOINTIMA; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK REDUCTION; UPREGULATION; VASCULAR ACCESS; VEGF A GENE; VEIN DISEASE; VEIN NEOINTIMAL HYPERPLASIA; VEIN OCCLUSION;

ACTINS; ANIMALS; APOPTOSIS; ARTERIOVENOUS SHUNT, SURGICAL; CAROTID ARTERIES; CASPASE 3; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CONSTRICTION, PATHOLOGIC; DISEASE MODELS, ANIMAL; GRAFT OCCLUSION, VASCULAR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERPLASIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; JUGULAR VEINS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MYOFIBROBLASTS; NEOINTIMA; NIH 3T3 CELLS; RENAL DIALYSIS; SIGNAL TRANSDUCTION; SIMVASTATIN; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84881161382     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.112     Document Type: Article

References (54)

1. Collins AJ, Kasiske B, Herzog C et al. Excerpts from the United States Renal Data System 2003 Annual Data Report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2003; 42: A5-A7.
2. Rooijens PPGM, Tordoir JHM, Stijnen T et al. Radiocephalic wrist arteriovenous fistula for hemodialysis: meta-analysis indicates a high primary failure rate. Eur J Vasc Endovasc Surg 2004; 28: 583-589. (Pubitemid 39462648)
3. Rekhter M, Nicholls S, Ferguson M et al. Cell proliferation in human arteriovenous fistulas used for hemodialysis. Arterioscler Thromb 1993; 13: 609-617. (Pubitemid 23107135)
4. Swedberg SH, Brown BG, Sigley R et al. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 1989; 80: 1726-1736. (Pubitemid 20031704)
5. Roy-Chaudhury P, Kelly BS, Miller MA et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001; 59: 2325-2334. (Pubitemid 32467627)
6. Misra S, Doherty MG, Woodrum D et al. Adventitial remodeling with increased matrix metalloproteinase-2 activity in a porcine arteriovenous polytetrafluoroethylene grafts. Kidney Int 2005; 68: 2890-2900. (Pubitemid 43251037)
7. Li L, Terry CM, Blumenthal DK et al. Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. Nephrol Dial Transplant 2007; 22: 3139-3146. (Pubitemid 350202566)
8. Wang Y, Krishnamoorthy M, Banerjee R et al. Venous stenosis in a pig arteriovenous fistula model anatomy, mechanisms and cellular phenotypes. Nephrol Dial Transplant 2007; 22: 3139-3146.
9. Bhardwaj S, Roy H, Heikura T et al. VEGF-A, VEGF-D and VEGFD (DeltaNDeltaC) induced intimal hyperplasia in carotid arteries. Eur J Clin Invest 2005; 35: 669-676. (Pubitemid 41640902)
10. Di Marco GS, Reuter S, Hillebrand U et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 2009; 20: 2235-2245.
11. Hutter R, Carrick FE, Valdiviezo C et al. Vascular endothelial growth factor regulates reendothelialization and neointima formation in a mouse model of arterial injury. Circulation 2004; 110: 2430-2435. (Pubitemid 39407350)
12. Inoue M, Itoh H, Ueda M et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of vegf in progression of atherosclerosis. Circulation 1998; 98: 2108-2116. (Pubitemid 28527469)
13. Simons M. VEGF and restenosis: the rest of the story. Arterioscler Thromb Vasc Biol 2009; 29: 439-440.
14. Shiojima I, Walsh K. The role of vascular endothelial growth factor in restenosis: the controversy continues. Circulation 2004; 110: 2283-2286. (Pubitemid 39407327)
15. Zhao Q, Egashira K, Hiasa K et al. Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury. Arterioscler Thromb Vasc Biol 2004; 24: 2284-2289. (Pubitemid 39658030)
16. Ohtani K, Egashira K, Hiasa K-i et al. Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. Circulation 2004; 110: 2444-2452. (Pubitemid 39407352)
17. Misra S, Fu AA, Puggioni A et al. Increased shear stress with up regulation of VEGF-A and its receptors and MMP-2, MMP-9, and TIMP-1 in venous stenosis of hemodialysis grafts. Am J Physiol Heart Circ Physiol 2008; 294: H2219-H2230.
18. Misra S, Shergill U, Yang B et al. Increased expression of HIF-1alpha, VEGFA and its receptors, MMP-2, TIMP-1, and ADAMTS-1 at the venous stenosis of arteriovenous fistula in a mouse model with renal insufficiency. J Vasc Interv Radiol 2010; 21: 1255-1261.
19. Yang B, Shergill U, Fu AA et al. The mouse arteriovenous fistula model. J Vasc Interv Radiol 2009; 20: 946-950.
20. Porter KE, Naik J, Turner NA et al. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 2002; 36: 150-157. (Pubitemid 41122904)
21. Turner NA, Midgley L, O'Regan DJ et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol 2007; 50: 458-461. (Pubitemid 350303825)
22. Turner NA, O'Regan DJ, Ball SG et al. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J 2005; 19: 804-806. (Pubitemid 40617390)
23. Misra S, Fu AA, Rajan DK et al. Expression of hypoxia inducible factor-1 alpha, macrophage migration inhibition factor, matrix metalloproteinase-2 and -9, and their inhibitors in hemodialysis grafts and arteriovenous fistulas. J Vasc Interv Radiol 2008; 19: 252-259.
24. Shay-Salit A, Shushy M, Wolfovitz E et al. VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells. Proc Natl Acad Sci USA 2002; 99: 9462-9467. (Pubitemid 34764636)
25. Das M, Burns N, Wilson SJ et al. Hypoxia exposure induces the emergence of fibroblasts lacking replication repressor signals of PKC{zeta} in the pulmonary artery adventitia. Cardiovasc Res 2008; 78: 440-448. (Pubitemid 351769755)
26. Misra S, Fu AA, Misra KD et al. Hypoxia-induced phenotypic switch of fibroblasts to myofibroblasts through a matrix metalloproteinase 2/tissue inhibitor of metalloproteinase-mediated pathway: implications for venous neointimal hyperplasia in hemodialysis access. J Vasc Interv Radiol 2010; 21: 896-902.
27. Misra S, Fu A, Anderson J et al. The rat femoral arteriovenous fistula model: Increased expression of MMP-2 and MMP-9 at the venous stenosis. J Vasc Interv Radiol 2008; 19: 587-594. (Pubitemid 351423659)
28. Fukumoto Y, Libby P, Rabkin E et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103: 993-999. (Pubitemid 32183806)
29. Chen Z, Fukutomi T, Zago AC et al. Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. Circulation 2002; 106: 20-23. (Pubitemid 34747436)
30. Porter KE, Turner NA, O'Regan DJ et al. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc Res 2004; 61: 745-755. (Pubitemid 38249473)
31. Rotmans JI, Velema E, Verhagen HJ et al. Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg 2004; 39: 432-439. (Pubitemid 38174330)
32. Bellosta S, Via D, Canavesi M et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671-1678. (Pubitemid 28521054)
33. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003; 23: 769-775. (Pubitemid 36566165)
34. Porter KE, Turner NA, O'Regan DJ et al. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res 2004; 64: 507-515. (Pubitemid 39505429)
35. Urbich C, Dernbach E, Zeiher AM et al. Double-edged role of statins in angiogenesis signaling. Circ Res 2002; 90: 737-744. (Pubitemid 34640894)
36. Weis M, Heeschen C, Glassford AJ et al. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-745. (Pubitemid 34157379)
37. Kureishi Y, Luo Z, Shiojima I et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-1010.
38. Gerber HP, McMurtrey A, Kowalski J et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 30-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-30343. (Pubitemid 28545503)
39. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009. (Pubitemid 26338729)
40. Campbell MJ, Esserman LJ, Zhou Y et al. Breast cancer growth prevention by statins. Cancer Res 2006; 66: 8707-8714. (Pubitemid 44449187)
41. Baetta R, Donetti E, Comparato C et al. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol Res 1997; 36: 115-121. (Pubitemid 27460408)
42. Zhang L, Lu H, Huang J et al. Simvastatin exerts favourable effects on neointimal formation in a mouse model of vein graft. Eur J Vasc Endovasc Surg 2011; 42: 393-399.
43. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 2002; 22: 1452-1458.
44. Rodrigues Diez R, Rodrigues-Diez R, Lavoz C et al. Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-betaindependent process. PLoS One 2010; 5: e14145.
45. Watts KL, Spiteri MA. Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1323-L1332. (Pubitemid 39507212)
46. Ahmed AK, Haylor JL, El Nahas AM et al. Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring. Kidney Int 2007; 71: 755-763. (Pubitemid 46624020)
47. Chade AR, Zhu XY, Grande JP et al. Simvastatin abates development of renal fibrosis in experimental renovascular disease. J Hypertens 2008; 26: 1651-1660.
48. Wang H, Zhang M, Bianchi M et al. Fetuin (alpha 2-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules. Proc Natl Acad Sci USA 1998; 95: 14429-14434.
49. Medina RJ, O'Neill CL, Devine AB et al. The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS One 2008; 3: e2584.
50. Copaja M, Venegas D, Aranguiz P et al. Simvastatin induces apoptosis by a Rho-dependent mechanism in cultured cardiac fibroblasts and myofibroblasts. Toxicol Appl Pharmacol 2011; 255: 57-64.
51. Langer S, Kokozidou M, Heiss C et al. Chronic kidney disease aggravates arteriovenous fistula damage in rats. Kidney Int 2010; 78: 1312-1321.
52. Kokubo T, Ishikawa N, Uchida H et al. CKD accelerates development of neointimal hyperplasia in arteriovenous fistulas. J Am Soc Nephrol 2009; 20: 1236-1245.
53. Pisoni R, Barker-Finkel J, Allo M. Statin therapy is not associated with improved vascular access outcomes. Clin J Am Soc Nephrol 2010; 5: 1447-1450.
54. Wilson SH, Simari RD, Best PJ et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001; 21: 122-128. (Pubitemid 32061936)